Pharma marketers in the U.S. sometimes use celebrities as spokespeople for their branded drugs or for non-branded campaigns. Such celebrities include TV personalities, athletes, movie stars and others who have thousands or millions of fans, Twitter followers, etc. Should Pharma Disclose Payments to Celebrity Spokespeople? This is just one of the issues explored in a recent survey of Pharma Marketing News readers.
There are enough legal issues in this case to keep a boatload of constitutional and pharma lawyers busy for years. But let's look at this from a different perspective -- i.e., what pharma has to gain from this and what patients have to lose.
Multichannel pharma marketing is conceptually relatively simple to understand, but incredibly difficult in practice, says Len Starnes, former Head of Digital Marketing & Sales, General Medicine at Bayer Schering Pharma. That said, multichannel is not a transient phenomenon, it's here to stay. Starnes hosted a survey on LinkedIn to answer the question: When will pharma marketing become de facto multichannel marketing in future?
Laura Kolodjeski (@lkolodjeski), Community Manager for Sanofi US Diabetes, sent me a Twitter DM announcing the launch of Diabetapedia (di-ah-bee-tah-pee-dee-ah), a new site 'to help meet educational needs of diabetes community.' According to Laura, the goal is to create 'a single, comprehensive place where anyone can find and share definitions of diabetes-related terms and phrases.' The site's tag line is 'Diabetes doesn't define you... so define diabetes.'
Although nearly two-thirds of respondents to a 2009/2010 Pharma Marketing News survey thought that using Twitter for patient support activities would be somewhat or very effective, relatively few pharmaceutical companies are doing this on a regular basis. From time to time, however, it does happen. Boehringer Ingelheim Shows How It's Done
Making Sense of Multichannel Marketing: Towards Achieving the “Holy Grail” of Marketing Effectiveness
This article summarizes the discussion lead by Starnes during a recent MultiChannel Webinar hosted by eyeforpharma, which is also hosting the 2nd Annual Multichannel and Mobile Strategy conference November 29-30, 2012, in London. Also speaking at the webinar was Tim White, Head of Digital Commercialization - Europe for Novartis, Benedikt Hoffmann, Head of eBusiness, Janssen, and Morten Kamp Jorgensen, Director, Corporate Brand & Reputation, at Vestas, a company that specializes in wind power solutions.
At the recent 6th Annual Digital Pharma East conference in Philadelphia, Bill Drummy, CEO of HeartBeat Ideas, argued that "With digital you can get way more bang for your buck, so you HAVE to think of the digital channel. Drummy's message was simple: the ROI of online promotion is an order of magnitude greater than the 'typical' 2:1 ROI for non-digital channel promotion. This may be true of small budget campiagns, but is it scaleable to the point where digital promotion gives you a significant bump in sales?
PharmaGuy (aka John Mack) presented the coveted bright yellow Hawaiian shirt/Pharmaguy Social Media Pioneer Award to Dennis Urbaniak, VP, Joan Mikardos, Senior Director, and Laura Kolodjeski, Senior Manager, Patient Solutions, at Sanofi US Diabetes. The award was made at the 6th Annual Digital Pharma East conference in Philadelphia on October 17, 2012. Accepting the award on behalf of the winners -- who could not make it in person -- was Wendy Blackburn of Intouch Solutions.
Twitter's new rules change the playing field for third party developers, establish caps on number of users, and shift guidelines to requirements across four categories of businesses. Will the new rules ruin the spirit of social media and are they bad for healthcare?
Pfizer Throws In the Lipitor Marketing Towel. Meanwhile AstraZeneca Promotes Crestor on Its Corporate...
Despite Pfizer's heroic and unprecedented effort to maintain Lipitor's market share after expiry last November and after spending more than $87 million promoting the medicine, the world's biggest drug company is quietly giving up on its once-great cash cow for good because more generic versions will soon be going on sale. Meanwhile, AstraZeneca promoted Crestor on its corporate blog. It's unusual for a pharmaceutical company to mention a product by brand name on its corporate blog. It's even more unusual to mention BOTH the product AND its indication -- because that would be promotion regulated by the FDA. But AstraZeneca has done just that on its 'AZ Health Connections' corporate blog. Why now? Can it be a purely opportunistic cheap shot?